Harness Therapeutics

Harness Therapeutics is a biotechnology company focused on developing next-generation therapies for neurodegenerative diseases. Their innovative approach centers on physiological protein upregulation, a unique strategy that aims to safely and effectively increase the levels of specific proteins involved in neurodegenerative pathways. Harness utilizes oligonucleotide-based methodologies to modulate the post-transcriptional regulation of protein synthesis, thereby increasing target protein levels in a highly controlled manner.

Harness Therapeutics has a strong focus on neurodegenerative diseases with a particular interest in Huntington's disease, ALS, and Alzheimer's. They are currently developing a pipeline of first-in-class therapeutics based on their proprietary platform. The company is driven by a passion to develop truly disease-modifying therapies that can slow or halt the progression of these devastating diseases, ultimately improving the lives of patients and their families.

Harness Therapeutics is a biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases. They focus on physiological protein upregulation, a novel approach that aims to safely and effectively increase the levels of specific proteins within the brain, with the goal of halting or even reversing the progression of these debilitating conditions. Their mission is to build a leading platform for this approach, enabling the development of truly disease-modifying therapies for Huntington's Disease, ALS, Alzheimer's, and other neurodegenerative disorders.

Harness Therapeutics promotes a culture of scientific innovation focused on developing life-changing therapies for neurodegenerative diseases. Their mission is driven by passion and a dedication to addressing unmet medical needs, emphasizing collaboration, expertise, and a commitment to delivering truly disease-modifying treatments.